Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
2 hedge funds and large institutions have $14K invested in Alexion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 6 closing their positions.
71% less funds holding
Funds holding: 7 → 2 (-5)
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
98% less capital invested
Capital invested by funds: $845K → $14K (-$831K)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$423K |
| 2 |
NICM
Neo Ivy Capital Management
New York
|
-$290K |
| 3 |
TAIM
TD Ameritrade Investment Management
Omaha,
Nebraska
|
-$85K |
| 4 |
Barclays
London,
United Kingdom
|
-$22K |
| 5 |
CFO
CVA Family Office
Denver,
Colorado
|
-$11K |
ALXN Hedge Fund Activity: Q4 2021 in Review
2 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2021, worth a combined $14K — down 98% from $845K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ALXN and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Brinker Capital Investments, exiting entirely with an estimated $423K sold.
- 2 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2021, down from 7 in Q3 2021.
- Funds reported $14K of Alexion Pharmaceuticals stock for Q4 2021, down 98% quarter-over-quarter.
- 1 fund opened new Alexion Pharmaceuticals positions in Q4 2021 and 6 closed out, a net change of -5 holders.
- The largest Alexion Pharmaceuticals seller in Q4 2021 was Brinker Capital Investments, an estimated $423K sold.
Based on aggregated 13F filings for Q4 2021.